Loading company…
Synendos Therapeutics develops treatments for neuropsychiatric disorders by modulating the endocannabinoid system.
Founded in 2019 in Switzerland, Synendos Therapeutics develops therapies for neuropsychiatric disorders. Its lead candidate, SYT-510, is a Selective Endocannabinoid Re-uptake Inhibitor (SERI) in clinical development for conditions including anxiety and PTSD. In April 2021, the company raised CHF 4.000 mn in Series A funding from Ysios Capital Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in